Seraph 100微结合亲和血液滤器治疗重型COVID-19的多中心评价
这项回顾性队列研究在9个ICU中评估Seraph 100微结合亲和血液滤器治疗COVID-19的安全性和疗效,比较53例接受Seraph 100治疗的患者与53例按研究中心匹配的对照患者。Seraph 100组患者更年轻、Charlson合并症指数和APACHE II评分更低;单因素分析显示Seraph 100组无升压药天数更多(发生率比1.30),校正后差异不显著;Seraph 100组死亡率低于对照组(32.1% vs 64.2%,p=0.001),校正后仍显著,但采用外部对照组的post hoc分析未观察到死亡率差异。在全部86例接受治疗的患者共177次治疗中,仅记录3例严重不良事件。作者认为,尽管各终点和比较未一致显示显著临床获益,但广谱、病原体不可知血液净化可安全部署以应对新病原体威胁。
要点
- 9个ICU的回顾性队列中,53例Seraph 100治疗患者与53例按研究中心匹配的对照相比,死亡率32.1% vs 64.2%(p=0.001),校正后仍显著。
- 采用外部对照组的post hoc分析未观察到死亡率差异,提示主结果需谨慎解读。
- 单因素分析Seraph 100组无升压药天数更多(发生率比1.30),校正后差异不显著。
- Seraph 100组基线更年轻(中位54岁 vs 64岁,p=0.009)、Charlson指数更低(2 vs 3,p=0.006)、APACHE II更低(12 vs 16,p=0.011)。
- 全部86例治疗患者共177次治疗中仅记录3例严重不良事件。
适用人群与场景
- 9个参与ICU的COVID-19患者,接受Seraph 100治疗者53例,按研究中心匹配的对照53例。
- 基线时两组在性别、种族/民族、体重指数和机械通气需求方面无差异。
处置流程与药物剂量
- 干预为Seraph 100微结合亲和血液滤器(ExThera Medical, Martinez, CA)体外治疗。
- 全部86例接受治疗的患者共进行177次治疗。
研究设计与关键结果
- 研究类型为回顾性队列研究,9个参与ICU,Seraph 100组53例、按研究中心匹配的对照组53例。
- Seraph 100组中位年龄54岁(IQR 41-65)vs 对照组64岁(IQR 56-69),p=0.009。
- Seraph 100组Charlson合并症指数中位2(IQR 0-3)vs 对照组3(IQR 2-4),p=0.006。
- Seraph 100组APACHE II评分中位12(IQR 9-17)vs 对照组16(IQR 12-21),p=0.011。
- 单因素分析Seraph 100组无升压药天数更多,发生率比1.30;校正后差异不显著。
- Seraph 100组死亡率32.1% vs 对照组64.2%(p=0.001),校正后仍显著;采用外部对照组的post hoc分析未观察到死亡率差异。
- 全部86例治疗患者共177次治疗中记录3例严重不良事件。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管该研究未在所有终点和比较中一致显示显著临床获益,但广谱、病原体不可知血液净化可安全部署以应对新病原体威胁,同时等待靶向治疗和疫苗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: The Seraph100 Microbind Affinity Blood Filter (Seraph 100) (ExThera Medical, Martinez, CA) is an extracorporeal therapy that can remove pathogens from blood, including severe acute respiratory syndrome coronavirus 2. The aim of this study was to evaluate safety and efficacy of Seraph 100 treatment for COVID-19.
DESIGN: Retrospective cohort study.
SETTING: Nine participating ICUs.
PATIENTS: COVID-19 patients treated with Seraph 100 (n = 53) and control patients matched by study site (n = 53).
INTERVENTION: Treatment with Seraph 100.
MEASUREMENTS AND MAIN RESULTS: At baseline, there were no differences between the groups in terms of sex, race/ethnicity, body mass index, and need for mechanical ventilation. However, patients in the Seraph 100 group were younger (median age, 54 yr; interquartile range [IQR], 41-65) compared with controls (median age, 64 yr; IQR, 56-69; p = 0.009). Charlson comorbidity index scores were lower in the Seraph 100 group (2; IQR, 0-3) compared with the control group (3; IQR, 2-4; p = 0.006). Acute Physiology and Chronic Health Evaluation II scores were also lower in Seraph 100 subjects (12; IQR, 9-17) compared with controls (16; IQR, 12-21; p = 0.011). The Seraph 100 group had higher vasopressor-free days with an incidence rate ratio of 1.30 on univariate analysis. This difference was not significant after adjustment. Seraph 100-treated subjects were less likely to die compared with controls (32.1% vs 64.2%; p = 0.001), a difference that remained significant after adjustment. However, no difference in mortality was observed in a post hoc analysis utilizing an external control group. In the full cohort of 86 treated patients, there were 177 total treatments, in which only three serious adverse events were recorded.
CONCLUSIONS: Although this study did not demonstrate consistently significant clinical benefit across all endpoints and comparisons, the findings suggest that broad spectrum, pathogen agnostic, blood purification can be safely deployed to meet new pathogen threats while awaiting targeted therapies and vaccines.
参考来源
- Chitty SA, Mobbs S, Rifkin BS, et al. A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19. Crit Care Explor. 2022. PMID: 35506015. doi:10.1097/CCE.0000000000000662
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。